Silence Therapeutics Appoints New Vice President of Research
Move Bolsters Scientific Team at Company's Research Center in Berlin
Silence Therapeutics plc announced the promotion of Jorg Kaufmann, Ph.D., to the position of vice president of research. In this new position, Dr. Kaufmann, who previously served as senior director, technologies at Silence, will play a key role in overseeing the Company's range of RNA interference (RNAi) research activities, including those focused on advancing Silence's novel small interfering RNA (siRNA) delivery technologies. Dr. Kaufmann will continue to be based at Silence's Berlin research center, where the Company is consolidating all research activities related to its novel RNAi therapeutic platforms.
Dr. Kaufmann possesses more than 13 years of biotechnology industry experience in both the United States and Europe. Since joining Silence in 2000, he has served as both senior and associate director, technologies at the Company's Berlin location. Prior to joining Silence, Dr. Kaufmann was a senior scientist at Chiron Corporation, where he was responsible for leading one of the company's molecular biology research groups focused on breast cancer. From 1996-1997 he served as a group leader at the Institute of Tumour Biology (IMT) in Marburg,Germany. Dr. Kaufmann was a postdoctoral fellow at the Howard Hughes Medical Institute,University of California, Los Angelesand received his Ph.D. in molecular biology from the Philipps University Marburg.
Topics
Organizations
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Roche acquires NimbleGen to gain entry into high-growth research microarrray market
EuropaBio Responds to the Eurobarometer on Biotechnology 2010

Evotec receives US$ 6.6 m grant for drug discovery in tuberculosis
Sartorius Reviews Fiscal 2013 Results
GVK Biosciences Joins ResearchPoint Global - Addition of India-based CRO expands reach of worldwide clinical organization
Major 'third-hand smoke' compound causes DNA damage
UCB announces start of the EXXELERATE clinical study in rheumatoid arthritis
Cangene signs agreement to supply the U.S. Department of Defense with VIG product

Mind Over Microbiome: How Mental States Impact Gut Health - New research reveals brain-gut circuit regulating immunity through microbiome modulation

€ 1 Million Research Grant Awarded for the First Time - Merck awarded a grant known as the Future Insight Prize for the first time
